By Dr Sebastian Leathersich, Fertility Specialist, Subiaco
Obesity affects one third of Australian women of reproductive age, and over half are overweight.
A growing number are turning to incretin-based treatments such as GLP-1 receptor agonists (RAs) and dual GLP-1/GIP RAs, with prescriptions among women aged 18-44 increasing seven-fold since 2011.
This aligns with international guidelines recommending pharmacotherapy as an adjunct to lifestyle interventions in adults who are obese or overweight with obesity-related comorbidities....
Obesity affects one third of Australian women of reproductive age, and over half are overweight.
A growing number are turning to incretin-based treatments such as GLP-1 receptor agonists (RAs) and dual GLP-1/GIP RAs, with prescriptions among women aged 18-44 increasing seven-fold since 2011.
This aligns with international guidelines recommending pharmacotherapy as an adjunct to lifestyle interventions in adults who are obese or overweight with obesity-related comorbidities....
This content is restricted to Medical Forum readers; this is a new feature. If you haven’t registered with our site in the last few weeks, please create a new account below. If you have subscribed, please log in.